nach oben

Reactions Weekly

Erschienen in:

01.06.2021 | Case report

Ribavirin/sofosbuvir/velpatasvir

Virological failure and myositis: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Identifying patient details (age and sex) of the patient, who developed myositis, have been obtained through direct communication with the author.

Wong YJ, et al. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Journal of Gastroenterology and Hepatology 36: 1300-1308, No. 5, May 2021. Available from: URL: http://doi.org/10.1111/jgh.15324

Titel: Ribavirin/sofosbuvir/velpatasvir
Virological failure and myositis: 5 case reports
Publikationsdatum: 01.06.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-97761-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Bosutinib/dasatinib/ponatinib

Biological or targeted synthetic DMARDs increase COVID-19 severity

Bosentan

Gentamicin

Plasma

Estrogen